Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Nerdwallet Inc (NRDS) Price & Performance

Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Nerdwallet Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Nerdwallet Inc trades at $9.74 (market cap $625.17M). The key difference: GSK plc is far larger — about 147× Nerdwallet Inc's market cap, and GSK plc pays a 3.9% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Nerdwallet Inc for 45 Days on average.

GSKNRDS
Market Cap
$91.88B$625.17M
Volume
7,730,5291,321,316
Sector
HealthMedia
52-Week High
$61.18$15.93
52-Week Low
$43.24$7.58
Typical Hold Time
93 Days45 Days
Enterprise Value
$111.88B$539.47M
Dividend Yield
3.9%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.

GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.79, up 7.76% with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with revenue growing from $539M in 2022 to $837M in 2025, though Q2 2026 earnings missed expectations. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81, while profitability metrics show ROE of 18.16% and net margin of 7.56%.

The stock presents a compelling growth story with accelerating revenue and improving margins, supported by 66.7% analyst buy ratings. Key risks include competitive pressure in organic search and execution challenges in maintaining earnings momentum. The positive cash flow trend and institutional support suggest potential for continued upside if the company can sustain its growth trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GSK
100% Buy0% Sell
Avg holding period · 93 Days
NRDS
0% Buy100% Sell
Avg holding period · 45 Days

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK →

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS →